Johns Hopkins ABX Guide
Lincomycin
INDICATIONS
FDA
FDA
- Treatment of serious infections caused by susceptible strains of streptococci, pneumococci, and staphylococci in PCN-allergic patients.
- Only IV formulation is available in U.S.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: March 4, 2018
Citation
Pham, Paul A, and John G Bartlett. "Lincomycin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540314/all/Lincomycin.
Pham PA, Bartlett JG. Lincomycin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540314/all/Lincomycin. Accessed December 6, 2023.
Pham, P. A., & Bartlett, J. G. (2018). Lincomycin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540314/all/Lincomycin
Pham PA, Bartlett JG. Lincomycin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2023 December 06]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540314/all/Lincomycin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Lincomycin
ID - 540314
A1 - Pham,Paul,Pharm.D.
AU - Bartlett,John,M.D.
Y1 - 2018/03/04/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540314/all/Lincomycin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
